MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 596745 | Name: LP 130

Description:

WARNING: This product is for research use only, not for human or veterinary use.

LP 130 is a retroviral protease inhibitor.

Chemical Structure

LP 130
LP 130
CAS#153314-49-9

Theoretical Analysis

MedKoo Cat#: 596745

Name: LP 130

CAS#: 153314-49-9

Chemical Formula: C46H58N6O9

Exact Mass: 838.4265

Molecular Weight: 839.00

Elemental Analysis: C, 65.85; H, 6.97; N, 10.02; O, 17.16

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
LP 130; LP-130; LP130;
IUPAC/Chemical Name
(4S,7S,10S,11S,15S)-15-(((S)-1-amino-3-(naphthalen-1-yl)-1-oxopropan-2-yl)carbamoyl)-11-hydroxy-10-isobutyl-7-isopropyl-4-(naphthalen-1-ylmethyl)-2,5,8,13-tetraoxo-3,6,9,14-tetraazaoctadecan-18-oic acid
InChi Key
CFJSRALSOWEJGV-WAGJPQHASA-N
InChi Code
InChI=1S/C46H58N6O9/c1-26(2)22-36(50-46(61)42(27(3)4)52-45(60)38(48-28(5)53)24-32-17-11-15-30-13-7-9-19-34(30)32)39(54)25-40(55)49-35(20-21-41(56)57)44(59)51-37(43(47)58)23-31-16-10-14-29-12-6-8-18-33(29)31/h6-19,26-27,35-39,42,54H,20-25H2,1-5H3,(H2,47,58)(H,48,53)(H,49,55)(H,50,61)(H,51,59)(H,52,60)(H,56,57)/t35-,36-,37-,38-,39-,42-/m0/s1
SMILES Code
O=C(N)[C@H](CC1=C2C=CC=CC2=CC=C1)NC([C@H](CCC(O)=O)NC(C[C@H](O)[C@@H](NC([C@H](C(C)C)NC([C@H](CC3=C4C=CC=CC4=CC=C3)NC(C)=O)=O)=O)CC(C)C)=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 839.00 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Huang HF, Huo XM, Huo LJ, Shen FJ, Wu LL. [Effect of valsartan on the expression of leptin, leptin receptor and collagen in rats with hepatic fibrosis]. Zhonghua Gan Zang Bing Za Zhi. 2018 Feb 20;26(2):119-124. doi: 10.3760/cma.j.issn.1007-3418.2018.02.009. Chinese. PubMed PMID: 29804378. 2: Ray KK, Stoekenbroek RM, Kallend D, Leiter LA, Landmesser U, Wright RS, Wijngaard P, Kastelein JJ. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Pre-Specified Secondary End Points in ORION 1. Circulation. 2018 May 7. pii: CIRCULATIONAHA.118.034710. doi: 10.1161/CIRCULATIONAHA.118.034710. [Epub ahead of print] PubMed PMID: 29735484. 3: Uznańska-Loch B, Wikło K, Trzos E, Wierzbowska-Drabik K, Chrzanowski Ł, Kasprzak JD, Kurpesa M. Advanced and traditional electrocardiographic risk factors in pulmonary arterial hypertension: the significance of ventricular late potentials. Kardiol Pol. 2018;76(3):586-593. doi: 10.5603/KP.a2017.0257. Epub 2018 Jan 3. PubMed PMID: 29297193. 4: Czubkowski P, Wierzbicka A, Pawłowska J, Jankowska I, Socha P. Obesity, lipid profiles and oxidative stress in children after liver transplantation. Acta Biochim Pol. 2017;64(4):661-665. doi: 10.18388/abp.2017_1623. Epub 2017 Dec 10. PubMed PMID: 29222858. 5: DePietro M, Gilbert I, Millette LA, Riebe M. Inhalation device options for the management of chronic obstructive pulmonary disease. Postgrad Med. 2018 Jan;130(1):83-97. doi: 10.1080/00325481.2018.1399042. Epub 2017 Dec 5. Review. PubMed PMID: 29210318. 6: Cano PG, Gamage LNA, Marciniuk K, Hayes C, Napper S, Hayes S, Griebel PJ. Lambda display phage as a mucosal vaccine delivery vehicle for peptide antigens. Vaccine. 2017 Dec 19;35(52):7256-7263. doi: 10.1016/j.vaccine.2017.11.010. Epub 2017 Nov 16. PubMed PMID: 29153779. 7: Zhou J, Zhang Q, Wang Y, Gao P, Chen D. The effect and safety of anacetrapib in the treatment of dyslipidemia: a systematic review and meta-analysis. Postgrad Med. 2018 Jan;130(1):129-136. doi: 10.1080/00325481.2018.1401421. Epub 2017 Nov 14. Review. PubMed PMID: 29135318. 8: Arsenault BJ, Petrides F, Tabet F, Bao W, Hovingh GK, Boekholdt SM, Ramin-Mangata S, Meilhac O, DeMicco D, Rye KA, Waters DD, Kastelein JJP, Barter P, Lambert G. Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk. J Clin Lipidol. 2018 Jan - Feb;12(1):130-136. doi: 10.1016/j.jacl.2017.10.001. Epub 2017 Oct 12. PubMed PMID: 29103916. 9: Kochkin AD, Gallyamov EA, Medvedev VL, Biktimirov RG, Martov AG, Sevryukov FA, Novikov AB, Sanzharov AE, Sergeev VP. [Laparoscopic pyelolithotomy for staghorn kidney stones. multi-center study]. Urologiia. 2017 Jul;(3):40-45. Russian. PubMed PMID: 28845937. 10: Stein EA, Dann EJ, Wiegman A, Skovby F, Gaudet D, Sokal E, Charng MJ, Mohamed M, Luirink I, Raichlen JS, Sundén M, Carlsson SC, Raal FJ, Kastelein JJP. Efficacy of Rosuvastatin in Children With Homozygous Familial Hypercholesterolemia and Association With Underlying Genetic Mutations. J Am Coll Cardiol. 2017 Aug 29;70(9):1162-1170. doi: 10.1016/j.jacc.2017.06.058. PubMed PMID: 28838366. 11: Zhong Y, Ye F, You W, Wu ZM. [Correlation between serum inflammatory cytokine levels and fibrous cap thickness of fibrofatty plaque in coronary culprit lesions]. Zhonghua Xin Xue Guan Bing Za Zhi. 2017 Jul 24;45(7):566-571. doi: 10.3760/cma.j.issn.0253-3758.2017.07.004. Chinese. PubMed PMID: 28738484. 12: Antonopoulos S, Mylonopoulou M, Angelidi AM, Kousoulis AA, Tentolouris N. Association of matrix γ-carboxyglutamic acid protein levels with insulin resistance and Lp(a) in diabetes: A cross-sectional study. Diabetes Res Clin Pract. 2017 Aug;130:252-257. doi: 10.1016/j.diabres.2017.06.015. Epub 2017 Jun 19. PubMed PMID: 28654853. 13: Li K, Mu ZL, Chen X, Wen GD, Zhao Y, Zhang JZ. Atopic Dermatitis-like Graft-versus-host Disease and Lichen Planus-like Graft-versus-host Disease: Alterations in Skin Barrier Function and Related Molecules. Chin Med J (Engl). 2017 Jun 20;130(12):1459-1466. doi: 10.4103/0366-6999.207475. PubMed PMID: 28584210; PubMed Central PMCID: PMC5463477. 14: Lai CL, Xing JP, Liu XH, Qi J, Zhao JQ, Ji YR, Yang WX, Yan PJ, Luo CY, Ruan LF. Relationships of Inflammatory Factors and Risk Factors with Different Target Organ Damage in Essential Hypertension Patients. Chin Med J (Engl). 2017 Jun 5;130(11):1296-1302. doi: 10.4103/0366-6999.206343. PubMed PMID: 28524828; PubMed Central PMCID: PMC5455038. 15: Yi YH, Yang Z, Han YW, Huai J. Effects of Rapamycin on Clinical Manifestations and Blood Lipid Parameters in Different Preeclampsia-like Mouse Models. Chin Med J (Engl). 2017 May 5;130(9):1033-1041. doi: 10.4103/0366-6999.204924. PubMed PMID: 28469097; PubMed Central PMCID: PMC5421172. 16: Oliver JA, Zeidan OA, Meeks SL, Shah AP, Pukala J, Kelly P, Ramakrishna NR, Willoughby TR. The Mobius AIRO mobile CT for image-guided proton therapy: Characterization & commissioning. J Appl Clin Med Phys. 2017 May;18(3):130-136. doi: 10.1002/acm2.12084. Epub 2017 Apr 24. PubMed PMID: 28436155; PubMed Central PMCID: PMC5689854. 17: Nicholls SJ, Ray KK, Ballantyne CM, Beacham LA, Miller DL, Ruotolo G, Nissen SE, Riesmeyer JS; ACCENTUATE Investigators. Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial. Atherosclerosis. 2017 Jun;261:12-18. doi: 10.1016/j.atherosclerosis.2017.04.008. Epub 2017 Apr 8. PubMed PMID: 28412650. 18: Waldmann E, Vogt A, Crispin A, Altenhofer J, Riks I, Parhofer KG. Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (The MICA-Study). Atherosclerosis. 2017 Apr;259:20-25. doi: 10.1016/j.atherosclerosis.2017.02.019. Epub 2017 Feb 24. PubMed PMID: 28279833. 19: Guliev BG. [Laparoscopic pyeloplasty for hydronephrosis of horseshoe kidney]. Urologiia. 2016 Nov;(5):58-62. Russian. PubMed PMID: 28248022. 20: Bramlage CP, Kröplin J, Wallbach M, Minguet J, Smith KH, Lüders S, Schrader J, Patschan S, Gross O, Deutsch C, Bramlage P, Müller GA, Koziolek M. Management of cardiovascular risk factors in patients with ANCA-associated vasculitis. J Eval Clin Pract. 2017 Aug;23(4):747-754. doi: 10.1111/jep.12709. Epub 2017 Feb 16. PubMed PMID: 28205311.

View History

Sulfaperin

Sulfaperin